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Has the ‘Fast-Track’ referral system affected
the route of presentation and/or clinical
outcomes in patients with colorectal
cancer?
Luke Thornton1*, Harriet Reader1, Stevan Stojkovic2, Victoria Allgar1 and Nick Woodcock2
Abstract
Background: The aim of this study is to determine whether the ‘Fast-Track’ referral system has changed the route
by which patients present with colorectal cancer (CRC) and whether the route of presentation has any effect on
clinical outcome.
Methods: A retrospective cohort study of patients diagnosed with CRC under the care of two consultant colorectal
surgeons between April 2006 and December 2012. The route by which patients presented was categorised as
Fast-Track (FT), non-Fast-Track (non-FT) or acute. Outcome variables were operative intent, disease stage and
2- and 5-year survival.
Results: A total of 558 patients were identified. One hundred ninety-seven patients (35.3 %) were referred as FT,
108 (19.4 %) presented acutely and 253 patients (45.3 %) presented via other routes (non-FT). Over the study
period, the route of presentation did not change significantly (P = 0.135). There was no significant difference
between FT and non-FT groups in terms of the proportion of patients undergoing potentially curative surgery
(70.6 vs 74.3 %, P = 0.092) or with node-negative disease (48.2 vs 52.2 %, P = 0.796) nor was there any difference in
2-year or 5-year survival (74.1 vs 73.9 %, P = 0.837 and 52.3 vs 53.8 %, P = 0.889, respectively). Patients who
presented acutely were less likely to undergo curative resection, had more advanced disease and had worse
2- and 5-year survival.
Conclusions: The Fast-Track referral system has not affected the route by which patients present with CRC nor has
it had any effect on clinical outcomes. Alternative strategies are required if the desired improvement in outcomes is
to be achieved.
Keywords: Colorectal, Cancer, General, Surgery, Outcomes, Survival
Background
Colorectal cancer (CRC) is the fourth most common
cancer and the second commonest cause of cancer-
related death in the UK, with over 40,000 new cases and
approximately 16,000 deaths per year [1–3]. The current
5-year survival in the UK is 54.4 % in men and 55.1 % in
women, but as high as 90 % if diagnosed at its earliest
stage (Dukes’ A) [4]. This compares unfavourably with
elsewhere in Europe, where survival rates are 8–12 %
higher [5]. This disparity is perceived as being due to a
reluctance of patients to consult their GP with bowel-
related symptoms, delays in referral of patients from pri-
mary to secondary care and/or delays in both investiga-
tion and subsequent treatment once referred [6].
In 2000, the UK Department of Health introduced the
‘Fast-Track’ or ‘Two Week Wait’ system for patients
with suspected cancer [7], in an attempt to address some
of these issues. This system applies to all the common
cancers, including CRC. For patients fulfilling any of the
agreed referral criteria, the GP completes a standardised
referral proforma (Fig. 1). Patients referred in this way
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and then have to be seen in secondary care within
14 days of referral, and if they are subsequently diag-
nosed with CRC, they have to commence treatment
within 62 days of the original GP referral. These targets
have inevitably exerted a considerable strain on re-
sources in secondary care. Further, a large proportion of
patients with CRC present via other routes: non-Fast-
Track referrals to the colorectal clinic and other special-
ties, e.g. Gastroenterology, the National Bowel Cancer
Screening Programme and emergency admissions.
The aims of this study were to (1) determine whether
the Fast-Track system has changed the route by which
patients present with CRC and (2) assess whether the
route of presentation has any effect on outcomes, in
terms of treatment intent, disease stage or survival.
Methods
All patients diagnosed with CRC under the care of two
consultant colorectal surgeons between April 2006 and
December 2012 were identified from the responsible
consultants’ personal prospective databases. For each pa-
tient, the following variables were recorded: age, gender,
route of referral, treatment intent (curative or palliative),
disease stage, and survival at 2 and 5 years. All research
Fig. 1 Fast-Track referral proforma
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carried out is in compliance with the Helsinki Declar-
ation. Study is approved by the York District Hospital
Clinical Effectiveness Team.
Statistical analysis
Chi-squared tests were used to compare categorical vari-
ables and ANOVA or independent t tests for continuous
variables. Kaplan-Meier curves were undertaken for sur-
vival data, with a log-rank test to compare referral
groups. Cox regression was used to investigate survival,
adjusting for age, sex and stage. All analyses were under-
taken on SPSS (v20). A P value of <0.05 was considered
to indicate statistical significance.
Results
A total of 558 patients with newly diagnosed CRC were
identified, of which 310 patients (55.6 %) were male,
with a median age of 73 years (IQR 64–80 years). Over-
all, 197 patients (35.3 %) were referred as a Fast-Track
(‘FT’ group), 108 (19.4 %) presented acutely (‘acute’
group) and 253 patients (45.3 %) presented via other
routes (‘non-FT’ group) (Table 1). The relatively small
number of patients diagnosed through the National
Bowel Cancer Screening Programme is explained by the
fact that it commenced in York only in February 2010.
The numbers of Fast-Track referrals per year are shown
in Fig. 2. There was an almost threefold increase from 551
in 2006 to 1425 in 2012. Over this time, there did appear to
be a slight increase in the proportion of CRC patients re-
ferred as Fast-Tracks, with a concomitant reduction in num-
bers of patients presenting acutely, though these changes
were not statistically significant (P = 0.135) (see Fig. 3).
A similar proportion of patients in the FT and non-FT
groups underwent potentially curative surgery (70.6 vs
74.3 %, P = 0.092), whereas significantly fewer acute patients
(50.9 %) underwent curative surgery (P < 0.001). Similarly,
equivalent proportions of FT and non-FT patients had
node-negative disease (48.2 vs 52.2 %, P = 0.796), whereas
the proportion of acute patients with node-negative disease
(27.8 %) was significantly lower (P < 0.0001).
The overall mean survival for all patients was 57.8 months.
Mean survival in the FT group was 52.7 months, compared
to 64.1 months in the non-FT group (P= 0.912). However,
mean survival in the acute patients was significantly lower
(28.0 months, P < 0.001). Cumulative survival for each of the
groups is shown in Fig. 4. There was no significant
difference between the FT and non-FT groups in terms of
either 2-year overall survival (74.1 vs 73.9 %, P= 0.837) or 5-
year overall survival (52.3 vs 53.8 %, P= 0.889). However,
both 2- and 5-year overall survival were significantly lower
in the acute group (38.2 %, P < 0.001 and 23.7 %, P < 0.001,
respectively).
Discussion
This study has shown that the Fast-Track system has not
affected the route by which patients present with colorectal
cancer. In particular, there has been no reduction in the pro-
portion of patients presenting acutely. Further, CRC patients
referred as a Fast-Track appear to do no better in terms of
curative surgery, disease stage or survival when compared to
non-Fast-Track patients, whereas those patients undergoing
emergency surgery do significantly worse.
The Fast-Track system was introduced to guarantee that
patients with symptoms suggestive of CRC are seen and in-
vestigated promptly when referred by their general practi-
tioner. Once diagnosed, the patients are subsequently
treated sooner than they would otherwise have been, with
the expectation that this will improve outcomes. There has
been an inexorable rise in the number of Fast-Track refer-
rals over the last few years: in the current study, there was
an almost threefold increase between 2006 and 2012. This
has placed an inevitable strain on resources in secondary
care. Having to process such large numbers of referrals in a
timely manner has encouraged hospital trusts to adopt vari-
ous investigative models, such as ‘straight-to-test’. Such
pathways are largely dictated by the needs of the local
population and the resources available. In York, all Fast-
Track referrals are seen in a designated clinic within
2 weeks, where they are assessed by a surgeon, and a deci-
sion made regarding the most appropriate investigation(s).
It is important to remember that only about 10 % of
Fast-Track patients actually have CRC [8, 9], and in the
current study, only just over a third of CRC patients were
referred as a Fast-Track. With such emphasis placed on
meeting the Fast-Track waiting time targets, it is vital that
this is not to the detriment of the majority of CRC pa-
tients who are not referred as a Fast-Track, whose investi-
gations and/or treatment could otherwise potentially be
delayed [10].
Bevis et al. similarly reported no significant differences
between Fast-Track and non-Fast-Track patients in terms
of the proportion of patients undergoing potentially cura-
tive surgery or disease stage [11], whereas other studies
found that Fast-Track patients actually had more
advanced disease [8, 9]. Further studies looking at survival
found no difference at either 2 years [12] or 5 years [13].
Table 1 Route of presentation
Route of presentation No. of patients (%)
Fast-Track 197 (35.3 %)





Acute 108 (19.4 %)
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Zafar et al. compared overall 5-year survival prior to and
following the introduction of the Fast-Track system and
found no difference [14].
There are various possible reasons as to why the Fast-
Track system appears to be failing to achieve its aim of
improving outcomes. The first possibility is that patients
are being referred inappropriately. To increase sensitivity,
the referral criteria are necessarily rather vague and open
to interpretation. This inevitably reduces specificity, with
consequent referral of significant numbers of patients with
functional bowel disease and the ‘worried well’. Further,
many patients do not actually fulfil the referral criteria.
Chohan et al. found that only 73 % of Fast-Track referrals
fulfilled the criteria, whereas 92 % of the patients subse-
quently diagnosed with CRC did so [8]. Conversely,
patients with CRC who do fulfil the Fast-Track criteria
frequently are not referred accordingly [15].
Patients referred via the Fast-Track route are undoubt-
edly investigated more quickly and undergo treatment
sooner, but the difference is relatively small. In the study
by Zafar et al., the median time from referral to treatment
prior to the introduction of the Fast-Track system was
115 days, compared to 76 days after [14]. Another study
comparing Fast-Track and non-Fast-Track patients
Fig. 2 Number of Fast-Track referrals per year
Fig. 3 Changes in the route of presentation over time
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demonstrated a significant reduction in both time to be
seen by a colorectal specialist (median 31 vs 69 days) and
time to initiation of treatment (median 42.5 vs 57.5 days)
[11]. Whilst these differences are statistically significant,
such modest reductions in time to treatment are unlikely
to have a clinically significant impact on outcome.
Arguably more important delays occur prior to referral to
secondary care. Patients are often reluctant to consult their
GP with bowel-related symptoms, due to embarrassment,
fear or ignorance. A recent study reported that 61 % of pa-
tients with rectal bleeding had thoughts about cancer, com-
pared with only 29 % of those without rectal bleeding [16].
Alternatively, there may be a failure on the part of the GP
to refer. Khattak et al. found that 79 % of patients who pre-
sented acutely with CRC had previously consulted their GP
with symptoms, and in 38 % of all patients, it was more
than 6 weeks before they were referred [17]. A further study
looking at delays in diagnosis for various cancer types
found breast cancer to have the shortest delay in presenta-
tion and suggested that this may be due to more obvious
symptoms that are easily understood by patients, together
with a high-profile national screening programme [18]. If
this is true, then the National Bowel Cancer Screening
Programme of faecal occult blood testing, plus impending
flexible sigmoidoscopy screening, should hopefully serve to
increase public awareness of the disease. Further, the recent
‘Be Clear on Cancer’ campaign, consisting of adverts on
television, radio and in national newspapers and magazines,
was introduced to raise public awareness of the symptoms
of the disease, encourage patients to consult their GP and
increase referrals to secondary care.
The most effective way of improving clinical outcomes
must be to reduce the number of patients presenting as
an emergency with CRC, in whom both short- and long-
term outcomes are significantly worse. In the current
study, we observed no significant change in the proportion
of patients presenting acutely, despite a massive increase
in the numbers of patients being referred as Fast-Tracks.
This concurs with the latest National Bowel Cancer Audit
Annual Report, in which the proportion of patients pre-
senting acutely with CRC was 20.6 %, a figure that has
remained frustratingly static over the last few years [19].
It would have been useful to be able to compare out-
comes to those achieved prior to the introduction of the
Fast-Track system in 2000, but the two surgeons whose
patients are included did not commence their posts until
2006, so this data was not available. However, it is not un-
reasonable to presume that pre-2000 outcomes would
have been comparable to the non-FT patients. We recog-
nise that the patients included in the study constitute only
a proportion of the total number of CRC patients man-
aged by the unit, but as all newly diagnosed patients are
allocated equitably between each of the surgeons, the
patients studied should represent a true cross section of
the total, with no referral bias. A further limitation of the
current study is that we do not know the total number of
non-FT referrals, but the numerous and varied routes by
which patients can present with CRC means that this is al-
most impossible to ascertain. We do not have any data as
to the predictive power of various symptoms in predicting
the likelihood of a patient having CRC, but this was not
the aim of the study. Some patients referred as a Fast-
Fig. 4 Cumulative survival
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Track will inevitably be found to have other significant
pathology, both malignant and benign, e.g. inflammatory
bowel disease, but the primary reason for a Fast-Track re-
ferral must be a strong suspicion of CRC.
Conclusions
In conclusion, this study has shown that the Fast-Track
system has not affected the route by which patients
present with CRC nor has it had any impact on out-
comes. This is likely to be due to a combination of
inappropriate referrals, delays in referral and failure of
patients to seek medical attention with symptoms. Fur-
thermore, it is unlikely that shortening a patient’s inves-
tigative and treatment pathway by a few weeks at most
will make any difference to their outcome. Continued ef-
forts should be directed at raising public awareness of
the symptoms of bowel cancer and strongly encouraging
patients to consult their GP with such symptoms.
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